Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
[google_news title=”” keyword=”Heroin vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Heroin vaccine
- NIH Reports Lower Dose of Mpox Vaccine is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimenon April 28, 2024 at 5:49 am
NIH Reports Lower Dose of Mpox Vaccine is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimen ...
- A vaccine to combat antibiotic resistanceon April 27, 2024 at 2:00 pm
A team of researchers at Michigan State University have outlined an approach to combating a prevalent public health issue: the development of treatment-res | Technology ...
- Breakthrough Vaccine Shows High Protection Against Drug-Resistant Superbug in Miceon April 26, 2024 at 4:03 pm
Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi.
- New UTI vaccine wards off infection for years, early studies suggeston April 26, 2024 at 12:39 pm
More than 50% of the patients who used a new mouth-spray-based vaccine didn't have a UTI for up to nine years.
- Vaccines have a crucial role in tackling antimicrobial resistanceon April 26, 2024 at 10:04 am
Antimicrobial resistance is a leading cause of death and disability worldwide. In 2019, it caused over 1 million deaths globally and was linked to almost 5 million.
- U.K. Tests World-First Personalized Skin Cancer Vaccineon April 26, 2024 at 9:08 am
Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney, bladder and colon cancer.
- World-First mRNA Vaccine For Skin Cancer Commences Landmark Phase 3 Trialon April 26, 2024 at 7:02 am
A UK man has become one of the first to receive an experimental mRNA vaccine designed to prevent recurrence of melanoma skin cancer. Steve Young, a 52-year-old musician, had a stage II melanoma ...
- First mRNA skin-cancer vaccine starts UK trialon April 25, 2024 at 4:45 pm
A n important trial of the world's first "personalised" mRNA vaccine against the deadliest form of skin cancer - melanoma - is now under way in the UK. Steve Young, 52, from Stevenage, Herts, who had ...
- Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Resultson April 25, 2024 at 8:10 am
Key TakeawaysMerck beat earnings and revenue estimates on strong sales of its Keytruda cancer medicine and Gardasil HPV vaccine.The pharmaceutical giant explained that results would have been even ...
- Merck’s first-quarter results beat expectations amid healthy vaccine-sales growthon April 25, 2024 at 3:31 am
Merck on Thursday reported first-quarter results that beat analysts’ expectations amid strong sales of vaccines and cancer drug Keytruda.
via Bing News